All-trans Retinoic Acid, Arsenic Trioxide, and Anthracycline-based Chemotherapy Improves Outcome in Newly Diagnosed Acute Promyelocytic Leukemia Regardless of FLT3-ITD Mutation Status
| Autor: | Yong-Zhong Su, Hong-Fang Tao, Lin-Wei Xu |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male Acute promyelocytic leukemia Oncology medicine.medical_specialty Anthracycline medicine.medical_treatment Retinoic acid Tretinoin Newly diagnosed medicine.disease_cause Biochemistry Young Adult chemistry.chemical_compound Arsenic Trioxide Leukemia Promyelocytic Acute Gene Duplication hemic and lymphatic diseases Internal medicine Antineoplastic Combined Chemotherapy Protocols Genetics Humans Medicine Idarubicin Anthracyclines Arsenic trioxide neoplasms Mutation Chemotherapy business.industry Prognosis medicine.disease fms-Like Tyrosine Kinase 3 chemistry Female business medicine.drug |
| Zdroj: | Current Medical Science. 41:491-497 |
| ISSN: | 2523-899X 2096-5230 |
| DOI: | 10.1007/s11596-021-2377-3 |
| Popis: | All-trans retinoic acid (ATRA) and pre-upfront arsenic trioxide (ATO) have revolutionized the therapy of acute promyelocytic leukemia (APL). However, internal tandem duplication of FMS-like tyrosine kinase 3 (FLT3-ITD) mutations is associated with increased risk of relapse. The aim of this study was to analyze the prognostic impact of FLT3-ITD on APL patients who received remission induction with ATRA, idarubicin (IDA) and/or ATO, followed by ATRA plus ATO along with anthracycline, as consolidation therapy. A total of 72 patients newly diagnosed with APL were included in this study. 83.3% of the patients achieved complete remission (CR) after induction therapy. FLT3-ITD mutations were detected in 16 (22.2%) patients and closely related to bcr-3 PML-RARa transcript (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink